FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004687570> ?p ?o ?g. }

• W2004687570 endingPage "1853" @default.
• W2004687570 startingPage "1842" @default.
• W2004687570 abstract "Background: Data regarding the pharmacokinetic properties of risperidone in the Thai population are limited. A new generic tablet formulation was recently developed, but bioequivalence research is necessary to obtain marketing authorization for it in Thailand. Objective: The aim of this study was to evaluate and compare the pharmacokinetic properties of risperidone and its active metabolite, 9-hydroxyrisperidone (which reportedly contributes to the drug's pharmacodynamic effects), in a newly developed generic tablet formulation (test) and a branded formulation (reference) in healthy, fasting, male Thai volunteers. Methods: A single-dose, randomized-sequence, doubleblind, 2-way crossover design was used in this study. The study took place from October 21 through November 28, 2007. After a ≥10-hour overnight fast, volunteers were orally administered one 2-mg risperidone tablet, either the test formulation (Condrug International Company, Ltd.) or the reference formulation—according to the randomization schedule—followed by a 14-day washout period and administration of the alternate formulation. Blood samples were collected over a period of 96 hours. Risperidone and 9-hydroxyrisperidone plasma concentrations were simultaneously determined using a validated HPLC/ion trap mass spectrometry method. The plasma concentration-time curves of the active moiety, risperidone, and 9-hydroxyrisperidone were generated for each volunteer, from which the Cmax, Tmax, AUC0-last, AUC0-∞, and t½ were determined using noncompart-mental analysis. The effects of formulation, period, sequence, and subject (within sequence) on pharmacokinetic parameters were analyzed using ANOVA. According to regulatory requirements set forth by Thailand, the Association of Southeast Asian Nations, and the US Food and Drug Administration, products meet the criteria for bioequivalence if the 90% CIs of the treatment ratios for Cmax and AUC are within the range of 0.80 to 1.25. Tolerability was assessed by patient interview, monitoring vital signs (ie, resting blood pressure, heart rate, body temperature), physical examination, and laboratory tests (ie, urinalysis, hematology, blood chemistry) before and after the study. Results: A total of 22 Thai male volunteers (mean [SD] age, 28.18 [8.27] years [range, 20.62–44.19 years]; weight, 62.43 [4.76] kg [range, 55.03–76.02 kg]; and body mass index, 21.76 [2.07] kg/m2 [range, 18.9924.91 kg/m2]) completed the study. The mean (SD) relative bioavailabilities of test to reference formulations determined from AUC of the active moiety, risperidone, and 9-hydroxyrisperidone were 1.06 (0.18), 1.07 (0.29), and 1.04 (0.17), respectively. The ANOVA suggested no statistically significant effect of formulation, period, or sequence on the studied pharmacokinetic parameters of the active moiety, risperidone, or 9-hydroxyrisperidone. The 90% CIs for the natural logarithm-transformed ratios of Cmax, AUC0-last, and AUC0-∞ were as follows: for active moiety, 0.94 to 1.03, 0.98 to 1.11, and 0.98 to 1.10, respectively; for risperidone, 0.90 to 1.10, 0.96 to 1.13, and 0.96 to 1.14, respectively; and for 9-hydroxyrisperidone, 0.91 to 1.03, 0.97 to 1.10, and 0.96 to 1.09, respectively. All met the criteria for bioequivalence. The most commonly reported adverse events (AEs) were somnolence (100.0%), orthostatic hypotension (13.6%), headache (4.5%), and syncope (2.3%). AEs were mild and disappeared within 1 day. No volunteers withdrew from the study because of AEs. Conclusions: The single-dose pharmacokinetic data in this small, all-male, selected sample of fasting, healthy volunteers met Thailand's regulatory criteria for assuming bioequivalence of the tested generic and reference 2-mg risperidone tablets. Both formulations were well tolerated." @default.
• W2004687570 created "2016-06-24" @default.
• W2004687570 creator A5024093574 @default.
• W2004687570 creator A5048921601 @default.
• W2004687570 creator A5050531726 @default.
• W2004687570 creator A5075444730 @default.
• W2004687570 date "2010-09-01" @default.
• W2004687570 modified "2023-09-26" @default.
• W2004687570 title "Relative bioavailability and pharmacokinetic comparison of two 2-mg risperidone tablet formulations: A single dose, randomized-sequence, double-blind, 2-way crossover study in healthy male volunteers in thailand" @default.
• W2004687570 cites W153750880 @default.
• W2004687570 cites W181223444 @default.
• W2004687570 cites W1964688493 @default.
• W2004687570 cites W1966439856 @default.
• W2004687570 cites W1976032493 @default.
• W2004687570 cites W1983858391 @default.
• W2004687570 cites W1988216543 @default.
• W2004687570 cites W2010906896 @default.
• W2004687570 cites W2018434135 @default.
• W2004687570 cites W2018925976 @default.
• W2004687570 cites W2040538157 @default.
• W2004687570 cites W2043716119 @default.
• W2004687570 cites W2068443264 @default.
• W2004687570 cites W2071742389 @default.
• W2004687570 cites W2075321548 @default.
• W2004687570 cites W2081450830 @default.
• W2004687570 cites W2131658797 @default.
• W2004687570 cites W2139651041 @default.
• W2004687570 cites W2170870858 @default.
• W2004687570 cites W2329519482 @default.
• W2004687570 doi "https://doi.org/10.1016/j.clinthera.2010.09.013" @default.
• W2004687570 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21194608" @default.
• W2004687570 hasPublicationYear "2010" @default.
• W2004687570 type Work @default.
• W2004687570 sameAs 2004687570 @default.
• W2004687570 citedByCount "6" @default.
• W2004687570 countsByYear W20046875702012 @default.
• W2004687570 countsByYear W20046875702013 @default.
• W2004687570 countsByYear W20046875702014 @default.
• W2004687570 countsByYear W20046875702017 @default.
• W2004687570 countsByYear W20046875702018 @default.
• W2004687570 crossrefType "journal-article" @default.
• W2004687570 hasAuthorship W2004687570A5024093574 @default.
• W2004687570 hasAuthorship W2004687570A5048921601 @default.
• W2004687570 hasAuthorship W2004687570A5050531726 @default.
• W2004687570 hasAuthorship W2004687570A5075444730 @default.
• W2004687570 hasConcept C112705442 @default.
• W2004687570 hasConcept C118552586 @default.
• W2004687570 hasConcept C142724271 @default.
• W2004687570 hasConcept C181389837 @default.
• W2004687570 hasConcept C204787440 @default.
• W2004687570 hasConcept C22979827 @default.
• W2004687570 hasConcept C27081682 @default.
• W2004687570 hasConcept C2776412080 @default.
• W2004687570 hasConcept C2776768635 @default.
• W2004687570 hasConcept C2780057945 @default.
• W2004687570 hasConcept C2908647359 @default.
• W2004687570 hasConcept C42404028 @default.
• W2004687570 hasConcept C6557445 @default.
• W2004687570 hasConcept C71924100 @default.
• W2004687570 hasConcept C86803240 @default.
• W2004687570 hasConcept C87813604 @default.
• W2004687570 hasConcept C98274493 @default.
• W2004687570 hasConcept C99454951 @default.
• W2004687570 hasConceptScore W2004687570C112705442 @default.
• W2004687570 hasConceptScore W2004687570C118552586 @default.
• W2004687570 hasConceptScore W2004687570C142724271 @default.
• W2004687570 hasConceptScore W2004687570C181389837 @default.
• W2004687570 hasConceptScore W2004687570C204787440 @default.
• W2004687570 hasConceptScore W2004687570C22979827 @default.
• W2004687570 hasConceptScore W2004687570C27081682 @default.
• W2004687570 hasConceptScore W2004687570C2776412080 @default.
• W2004687570 hasConceptScore W2004687570C2776768635 @default.
• W2004687570 hasConceptScore W2004687570C2780057945 @default.
• W2004687570 hasConceptScore W2004687570C2908647359 @default.
• W2004687570 hasConceptScore W2004687570C42404028 @default.
• W2004687570 hasConceptScore W2004687570C6557445 @default.
• W2004687570 hasConceptScore W2004687570C71924100 @default.
• W2004687570 hasConceptScore W2004687570C86803240 @default.
• W2004687570 hasConceptScore W2004687570C87813604 @default.
• W2004687570 hasConceptScore W2004687570C98274493 @default.
• W2004687570 hasConceptScore W2004687570C99454951 @default.
• W2004687570 hasIssue "10" @default.
• W2004687570 hasLocation W20046875701 @default.
• W2004687570 hasLocation W20046875702 @default.
• W2004687570 hasOpenAccess W2004687570 @default.
• W2004687570 hasPrimaryLocation W20046875701 @default.
• W2004687570 hasRelatedWork W2011337719 @default.
• W2004687570 hasRelatedWork W2035126646 @default.
• W2004687570 hasRelatedWork W2351830309 @default.
• W2004687570 hasRelatedWork W2355880357 @default.
• W2004687570 hasRelatedWork W2359939078 @default.
• W2004687570 hasRelatedWork W2363093019 @default.
• W2004687570 hasRelatedWork W2372787074 @default.
• W2004687570 hasRelatedWork W2376335381 @default.
• W2004687570 hasRelatedWork W2389356338 @default.
• W2004687570 hasRelatedWork W993345507 @default.
• W2004687570 hasVolume "32" @default.
• W2004687570 isParatext "false" @default.

• next